How EMPA-REG Has Changed My PracticeHow EMPA-REG Has Changed My Practice
The EMPA-REG Outcomes trial found that the diabetes drug empagliflozin was not only safe but it actually provided cardiovascular benefits in high-risk patients. Medscape Diabetes & Endocrinology
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Empagliflozin | Endocrinology | Heart | Jardiance